key: cord-0761713-xyykoor7
authors: Markewitz, Robert; Pauli, Daniela; Dargvainiene, Justina; Steinhagen, Katja; Engel, Sarah; Herbst, Victor; Zapf, Dorinja; Krüger, Christina; Sharifzadeh, Shahpour; Schomburg, Benjamin; Leypoldt, Frank; Rupp, Jan; Görg, Siegfried; Junker, Ralf; Wandinger, Klaus-Peter
title: The temporal course of T- and B-cell-responses to vaccination with BNT162b2 and mRNA-1273
date: 2021-09-20
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.09.006
sha: 6a1aadfd473fe7674e8d9e4635363eb2b1fa7bfc
doc_id: 761713
cord_uid: xyykoor7

OBJECTIVES: To investigate the immune systems’ response (and its influencing factors) to vaccination with BNT162b2 or mRNA-1273. METHODS: 531 vaccinees, recruited from health care professionals, donated samples before, in between, and after the administration of the two doses of the vaccine. T- and B-cell responses were examined via Interferon-γ-release assay as well as detection of antibodies against different epitopes of SARS-CoV-2 (S1 and NCP) via ELISA and binding surrogate neutralization assay. Results were correlated with influence factors such as age, sex, prior infection, vaccine received (BNT162b2 or mRNA-1273), and immunosuppression. Furthermore, antinuclear antibodies (ANA) were measured to screen for autoimmune responses following the vaccination with an mRNA vaccine. RESULTS: No markers of immunity against SARS-CoV-2 were found before the first vaccination. Two weeks after it, specific responses against SARS-CoV-2 were already measurable (median±median absolute deviation (MAD): anti-S1 IgG: 195.5±172.7 BAU/ml; IgA: 6.7±4.9 OD; surrogate neutralization: 39±23.7 %), which were significantly increased two weeks after the second dose (anti-S1 IgG: 3744±2571.4 BAU/ml; IgA: 12±0 OD; surrogate neutralization: 100±0 %, IFN-γ: 1897.2±886.7 mIU/ml). Responses were stronger for younger participants (this difference decreasing after the second dose). Further influences were previous infection with SARS-CoV-2 (causing significantly stronger responses after the first dose compared to unexposed individuals (p ≤ 0.0001)) and the vaccine received (significantly stronger reactions for recipients of mRNA-1273 after both doses (p < 0.05 – 0.0001)). Some forms of immunosuppression significantly impeded the immune response to the vaccination (with no observable immune response in three immunosuppressed participants). There was no significant induction of ANA by the vaccination (no change in qualitative ANA results (p = 0.2592), nor ANA titers (p = 0.08) from pre to post vaccination. CONCLUSIONS: Both vaccines elicit strong and specific immune responses against SARS-CoV-2, which become detectable one week (T-cell-response) or two weeks (B-cell-response) after the first dose.

Group t1 (0-6 days after first dose) t2 (14 days after first dose) t3 (14 days after second dose) IFN-γ (mIU/ml) Anti-S1 IgA (OD ratio)

Anti-S1 IgG (BAU/ml) Neutral. antibodies (%) Anti-S1 IgA (OD ratio)

Anti-S1 IgG (BAU/ml) Neutral. Ab (%) IFN-γ (mIU/ml) Anti-S1 IgA (OD ratio)

Anti-S1 IgG ( 

Since its onset in late 2019 (1) , the worldwide spread of the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to increasingly drastic public health measures with immense social, political, and economic consequences (2) (3) (4) . To achieve a sustainable containment of the pandemic, several vaccines against SARS-CoV-2 have been developed, BNT162b2 and mRNA-1273 being the first to be approved and administered since December 2020. While clinical data, both from the clinical trials (5-7) of these vaccines and "real-world" data from their application in the field (8-10), appear promising, their effects on the recipients immune systems remain to be studied further: On one hand, the efficacy of the vaccines, as measured by the detection of assumed correlates, both humoral and cellular, of immunity against SARS-CoV-2, needs to be well characterized. On the other hand, possible autoimmune events associated with the vaccines should be closely monitored, especially as there is considerable uncertainty among the general population concerning mRNA-based vaccines, owing to the novelty of their use in humans (11) as well as the unusually rapid process of their development and approval. To dispel this uncertainty as well as to cast further light on the development of assumed immunity against SARS-CoV-2 after vaccination is the goal of this study.

To this end, we examined the serological status of 531 vaccinees before, during, and after the vaccination against SARS-CoV-2, measuring different components of the immune response to the vaccination: binding antibodies against different target antigens of SARS-CoV-2 (the S1-subunit of the spike protein (anti-S1) as well as the nucleocapsid protein (anti-NCP)), the neutralizing capacity anti-S1 and the specific T-cell-response (via a SARS-CoV-2 specific Interferon-γ release assay (IGRA)) Further, we examined antinuclear antibodies (ANA) as a broad screening for the detection of antibodies against nuclear antigens, including mRNA. We hypothesized that 1) prior to the vaccination, the seroprevalence would be low, 2) vaccinees would develop antibodies specifically against the S1-subunit of the spike protein (and not against NCP), 3) in addition to the antibody response, vaccinees would develop a specific T-cell response against SARS-CoV-2, and that 4) vaccinees would show no development of antibodies against nuclear antigens, including RNA, as a consequence of the vaccination.

The study consisted of a series of tests performed on samples donated by the participants at different time points during the course of their vaccination against SARS-CoV-2: At the first time point (t1), shortly before or after the first dose of the vaccination, the sera were tested for anti-SARS-CoV-2 antibodies, ANA, as well as the T-cell response (via IGRA). For analytical purposes, all samples collected within six days after the first dose of the vaccination were considered as t1 (as not all participants were able to donate samples prior to the first dose). At a second time point (t2), two weeks after the first dose of the vaccination, anti-SARS-CoV-2 antibodies (IgG, IgA and neutralizing antibodies) were measured again. At a third time point (t3), two weeks after the second dose of the vaccination, all participants were again tested for anti-SARS-CoV-2 antibodies (IgG, IgA and neutralizing antibodies), ANA, and their T-cell response (IGRA).

Participants were recruited from healthcare workers of a German university hospital, who were prioritized to receive a vaccination against SARS-CoV-2 by the German SARS-CoV-2 vaccination roll-out campaign. More detailed information about the vaccination program can be found in the supplement.

For analytical purposes, data on age, sex and the specific vaccine received were collected from each participant. Other data, such as on immunosuppressive medication received by the participants, were disclosed voluntarily by some participants but not collected systematically.

All participants provided written informed consent. The study was approved by the University of Kiel institutional review board (AZ: D642/20). The study was conducted in accordance with the Declaration of Helsinki (12) .

Anti-S1 antibodies of the classes IgA and IgG, and anti-NCP IgG were measured via ELISA using kits by EUROIMMUNE (Lübeck, Germany) according to the manufacturers' instructions. Anti-S1 was chosen as target antigen, as it is a main part of the immunogenic antigen induced via vaccination with BNT162b2 or mRNA-1273. Anti-NCP was chosen to detect possible unrecognized infections with SARS-CoV-2, as antibodies against NCP are not to be expected after vaccination. Further information on the interpretation of these assays can be found in the supplement.

Neutralizing antibodies were examined via the SARS-CoV-2-NeutraLISA surrogate neutralization assay (EUROIMMUN, Lübeck, Germany), according to the manufacturer's instructions. Further information on this assay can be found in the supplementary material.

The T-cell-response to the vaccination against SARS-CoV-2 was examined using an Interferon-γ release assay (IGRA; EUROIMMUN, Lübeck, Germany), according to the manufacturers' instructions. Further information on the IGRA is provided in the supplement.

ANA were examined as a broad screening for autoantibodies against nuclear structures at t1 and t3. Indirect immunofluorescence microscopy (IIF) on the substrate HEp-20-10 (EUROIMMUN, Lübeck, Germany) according to the manufacturers' instructions. More detailed information on the examination of ANA is provided in the supplement.

For reporting averaged results, the median (measure of dispersion: median absolute deviation (MAD)) was used if not specified otherwise, as the data set contained many outliers and skewed distributions.

Due to the abovementioned distribution of parts of the data, tests for statistically significant differences in continuous variables between two groups were mainly performed via the Mann-Whitney U test (unless otherwise specified). Tests for correlations between continuous variables were performed by calculating Spearman's Rho. Statistical significance was assumed for p-values smaller than 0.05. All statistical analyses were performed using the open-source software for statistical computing and graphics R (version 4.0.4) with the integrated development environment RStudio (Version 1.1.463) (14) .

Overall, 531 participants were recruited. Of these, 389 (73.3 %) were female. The mean age at the time of reception of the first vaccine dose was 42.2 years (SD: ±12, range: 18-67).

There was no statistically significant difference in age between the sexes (t-test: t = 1.6954, df = 269.45, p = 0.09116). Figure S1 shows the distribution of age groups in both sexes. 481 (90.6 %) of participants received BNT162b2 and 50 (9.4 %) mRNA-1273, as determined by the availability of the vaccines.

Most, but not all samples were collected at the time scheduled by the study protocol: The median absolute deviations (MAD) of the day of sample collection for the different time points were: t1: ±1.5 days; range: -6 -27 days (of these, only those collected up until day six post vaccination were included in calculations of the baseline serologic status, as no vaccineinduced antibodies were to be expected within this time frame); t2: ± 0, range: 9 -37; and t3: ± 0, range: 39 -77). All medians (with median absolute deviation and respective group sizes) of all measured values at all time points can be gathered from Table 1 .

The first component of the immune response to become detectable was the T-cell response as measured via IGRA, the medians of which first crossed the threshold for positivity (200 mIU/ml IFN-γ) in samples collected on day seven after vaccination with 1083±914 mIU/ml. It was followed by anti-S1 IgA (crossing the threshold of 1.1 (OD ratio) at day ten with 1.23±1.3 (OD ratio)) and anti-S1 IgG (crossing the threshold of 35.2 BAU/ml at day 12 with 128.6±150.4 BAU/ml) as well as neutralizing antibodies (also crossing the threshold of 35 % at day 12 with 35±11.9 %; see Fig. 1 ). At t2, the responses reached a plateau, with IFN-γ and IgA showing a tendency to decrease again after peaks in samples collected nine and 17 days post vaccination, respectively. At t3, all measured responses exhibited significantly higher values (p < 0.0001) than at t2. All time points considered, all responses show highly significant correlations of medium to strong effect sizes with the amount of days since vaccination (See Fig. 2 ).

Of note, at t2, 22 participants did not yet develop an anti-S1 IgG response, and 190 did not develop levels of neutralizing antibodies considered to be reactive. At t3, the same is true for only three participants (see "Influence of Immunosuppression).

Influence of age: There is a highly significant inverse correlation of medium effect size between values and age at t2 for both anti-S1 IgG (R = -0.5, p < 0.0001) and neutralizing antibodies (R = -0.4, p < 0.0001). At t3, the same correlation can be observed with only small effect sizes for both anti-S1 IgG (R = -0. 26 3). For anti-S1 IgA, this correlation can only be shown at t2 (R = -0.32, p < 0.0001). For IFN-γ via IGRA (which was not performed at t2), an inverse correlation with age of only negligible effect size can be observed at t3 (R = -0.13, p = 0.004).

We could identify five participants with a self-reported, anamnestic history of COVID-19. These individuals already showed detectable immune responses against SARS-CoV-2 (including anti-NCP IgG) at t1 (anti-S1 IgG: 110±39.4 BAU/ml; anti-S1 IgA: 3.7±4.5 (OD ratio); neutralizing antibodies: 40±5.9 %; IFN-γ (IGRA): 1875.4±906.5 mIU/ml), which increased dramatically in size at t2 already (anti-S1 IgG: 3753.6±3415.9 BAU/ml; anti-S1 IgA: 12.0±0 (OD ratio); neutralizing antibodies: 100±0 %), reaching levels observed only after the second dose of the vaccination in previously uninfected individuals. For anti-S1 IgA, IgG and neutralizing antibodies, this difference between previously infected and uninfected individuals at t2 is statistically significant (p ≤ 0.0001). At t3, their responses (especially anti-S1 IgG: 3323.2±517.1 BAU/ml) did not increase further in size.

Eleven participants disclosed receiving immunosuppressive medication. While eight of these (receiving Dimethylfumarate, Methotrexate, Adalimumab or Certolizumab) did not show reduced immune responses compared to the rest of the cohort, three participants (receiving Rituximab, Fingolimod and Mycophenolate plus Belatacept, respectively) showed no immune response at any time point. Of note, information about immunosuppressive medication received by the vaccinees was not collected systematically but relied on the voluntary disclosure of this fact by participants during the course of the study.

At t2, significantly higher values (p < 0.0001) could be measured for anti-S1 IgG (512±415.1 vs. 183.4±155.4 BAU/ml), anti S1 IgA (11.0±1.4 vs. 6.2±4.8 (OD ratio)) and neutralizing antibodies (60.5±25.2 vs. 37±23.7) for patients receiving mRNA-1273 compared to BNT162b2. At t3, this difference could still be shown for anti-S1 IgG (p = 0.0453) and for IFNγ via IGRA (which was not performed at t2; p = 0.0051. Importantly, these differences cannot be explained by age differences between recipients of different vaccines as statistical analyses revealed none (t-test: t = -1.245, df = 58.821, p = 0.2181). See Fig. 4 for this comparison for anti-S1 IgG and neutralizing antibodies.

At no time point was there any relevant difference in any of the measured immune responses between the two sexes (no participant having self-declared a non-binary sexual identity).

The detailed results of the examination of antinuclear antibodies (ANA) can be found in the supplement. In brief, no short-term induction of ANA after vaccination against SARS-CoV-2 could be seen.

In general, the results of this study show that adults develop strong and specific immune responses to both examined anti-SARS-CoV-2 mRNA vaccines, both at the T-and the Bcell-level. Almost all participants developed high levels of all examined markers while there was no evidence of a vaccine-associated induction of antinuclear antibodies.

While the T-cell response (IFN-γ via IGRA) became detectable seven days after the first dose of the vaccination on average, the B-cell response (anti-S1 IgA and IgG) did so at ten or 12 days post vaccination, respectively (others having found timelines very similar to ours in intraindividual measurements (15) ). This timeline observed by us can be correlated with the clinical observation that the cumulative incidences of unvaccinated and vaccinated individuals start to diverge 12 days (6, 8) to 14 days (16) after the first dose. In synopsis with our data, this divergence is likely explained by the emergence of measurable levels of anti-SARS-CoV-2 IgG at exactly this point. This assumption is further supported by the fact that one of our participants was tested positive for SARS-CoV-2 via PCR ten days after having received the first dose of BNT162b2. One day prior to this, they had donated a sample already showing a strong T-cell response but no anti-S1 IgG yet, which suggests that the Tcell response alone, as measured via IGRA, is not sufficient to convey immunity against SARS-Cov-2. The fact that vaccine-induced clinical protection against SARS-CoV-2 becomes detectable at the same time as anti-S1 IgG does furthermore suggests that relatively low levels of anti-S1 IgG and neutralizing antibodies might already convey at least some degree of clinical protection (median anti-S1 IgG titer between days 12 and 35 after the first dose of the vaccine: 193.3±167.9 BAU/ml; median level of inhibition for the same time frame: 38±23.7 %). This assumption is supported by findings that even low levels of neutralizing antibodies convey protection against SARS-CoV-2 (17) .

Furthermore, the levels of all examined markers increased significantly after the second dose of the vaccine. This increase and the fact that a considerable share of participants did not develop levels of anti-S1 IgG and/or neutralizing antibodies considered to be reactive after the first dose of the vaccine are strong arguments in favor of administering both doses of the vaccine to all recipients, especially older ones. While older vaccinees have a general tendency to develop lower anti-S1 IgG titers and levels of neutralizing antibodies than younger vaccinees, this discrepancy is much more pronounced after the first dose of the vaccine than after the second one. Most likely, this is due to immune responses being delayed but also less pronounced for older individuals, a phenomenon generally summarized under the term immunosenescence (18) . A delay in immune responses of older recipients would explain why the age dependency of the markers examined by us is greater after the first dose of the vaccine, while a generally weaker response would explain why this dependency persists after the second dose. The same mechanisms may also underlie the heightened risk of older patients to develop a severe course of COVID-19 (19) (20) (21) . Therefore, while all age groups profit from the second dose, in regard to the levels of markers examined by us, older vaccinees do so even more, other studies having shown that this trend continues beyond the age groups we examined (22) . Nevertheless, there is as of yet no evidence to show that different antibody levels translate to different levels of clinical protection against SARS-CoV-2 Further, three participants did not develop any immune response at any time point, most likely as a consequence of immunosuppressive medication. Although the mechanisms of immunosuppression were very different between these three, both B-and T-cell response were absent for all of them. Although it can't be proven serologically, it must to date be assumed that a missing seroconversion translates to missing clinical protection against SARS-CoV-2. Other studies have also shown an impaired immune response to vaccination with BNT162b2, especially in patients with a liver or kidney transplant (23) (24) (25) . To counter possible adverse effects of a false sense of security it is therefore critical to identify nonresponders to the vaccination, as is usual for other vaccines as well. Other forms of immunosuppressive medication did not affect immune responses to the vaccination against SARS-CoV-2, as has been previously shown (26) .

In our cohort, a vaccination with mRNA-1273 elicited somewhat stronger immune responses than BNT162b2. It is doubtful, however, whether this translates to better clinical protection, as the differences, especially in neutralizing antibodies at t3, while statistically significant, are very small. Clinical data seem to suggest a very comparable efficacy for both vaccines (9) .

A further observation of our study is that individuals with a history of COVID-19 develop much higher antibody levels already after the first dose of the vaccination compared to unexposed recipients. While this has been shown before (27) (28) (29) (30) , we were also able to show that these vaccinees do not benefit further from a second dose of the vaccine, which could potentially be employed more efficiently if administered to another unexposed vaccinee.

An interesting side note of the examination of ANA in our cohort is the unusually high prevalence of the pattern AC-2. Considering the fact that AC-2 and its target antigen DFS70 are negatively associated with the presence of autoimmune diseases (31) , this observation serves to show that non-specific findings increase in frequency when tests are ordered without preselection. To avoid unnecessary diagnostics and therapy, a correct interpretation of these findings is all the more important.

Our study has several limitations: information on immunosuppressive medication, while being reported voluntarily by several participants, was not collected systematically. Neither was information collected about possible medical conditions, especially autoimmune ones, or other medication received by the participants. The impact of these factors may therefore have been underestimated, or not recognized at all. The share of participants receiving mRNA-1273 was considerably smaller, possibly underestimating the differences between both vaccines. The temporal course of the immune response after vaccination was gained through interindividually gathered data. Ideally, intraindividual measurements in short (ideally daily) intervals after the vaccination would be performed. Also, the interval between the second dose of the vaccine and the last collection of blood from was relatively short with two weeks. However, another follow-up measurement with a longer interval is in the planning at the time this manuscript was written. Lastly, our participants having been recruited from a population of employed individuals of working age, there may have been a bias towards more healthy individuals in our cohort.

In conclusion, we were able to show that mRNA-1273 and BNT162b2 elicit strong and specific immune responses that were significantly enhanced after the second dose. Important influence factors were age, prior infection, immunosuppression and the vaccine received. In light of recent evidence showing the antibody responses to the vaccines to be sustained (32, 33) , and the vaccines to be clinically effective (5, 6, (8) (9) (10) , our findings are encouraging signs that the available vaccines against SARS-CoV-2 may contribute decisively the containment of the COVID-19 pandemic. Figure 1 : Timeline of the interindividually measured kinetics of the different markers of the immune response to the first dose of the vaccination against SARS-CoV-2 presented as a function of days since the administration of the first dose: T-cell response as measured via IGRA (panel A), anti-S1 IgA (panel B), anti-S1 IgG (panel C), and neutralizing antibodies (panel D). Each boxplot represents one day since administration of the first dose, the jittered dots each individual measurement. The blue line indicates the smoothed means, with a grey confidence band of 95 %. In the upper left hand corner of each panel is spearman's rho for the correlation of x (days since first dose) and y (levels of the respective marker) of each panel, as well as its p-value. The dotted line indicates the respective cutoffs for positivity/reactivity of the different markers. Table 1 : Average values (reported via medians ± median absolute deviation) for all measured markers at all time points, including the respective group sizes, for the whole cohort and the following subgroups: women, men, participants previously infected with SARS-CoV-2, participants having received BNT162b2, and participants having received mRNA-1273 

A Novel Coronavirus from Patients with Pneumonia in China

Lack of safeguards in response to restrictive public health measures

Lockdown impact on COVID-19 epidemics in regions across metropolitan France

Impact of a nationwide COVID-19 lockdown on acute coronary syndrome referrals

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight

Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center

mRNA vaccines -a new era in vaccinology

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

Virological assessment of hospitalized patients with COVID-2019

R: A Language and Environment for Statistical Computing

Human IgG and IgA responses to COVID-19 mRNA vaccines

BNT162b2 vaccine uptake and effectiveness in UK healthcare workers -a single centre cohort study

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Impact of ageing on the response and repertoire of influenza virus-specific CD4 T cells

Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19

Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?

Clinical correlates of anti-SARS-CoV-2 antibody profiles in Spanish COVID-19 patients from a high incidence region. Sci Rep

Agedependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination

Antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients -Prospective cohort study

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination